Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma

Oncologist

Volumn 17, Issue 11, 2012, Pages 1376-1385

  Dequen, Pascale ^a   Lorigan, Paul ^b   Jansen, Jeroen P ^a,c   Van Baardewijk, Marc ^d   Ouwens, Mario J N M ^a   Kotapati, Srividya ^d  

^a The Christie NHS Foundation Trust ^*

^b CHRISTIE HOSPITAL   (United Kingdom)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Ipilimumab; Melanoma; Network meta analysis; Survival

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; ALPHA2B INTERFERON; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; GLYCOPROTEIN GP 100; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; PACLITAXEL; SORAFENIB; TAMOXIFEN; VINBLASTINE;

ABDOMINAL PAIN; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; FATIGUE; HUMAN; MELANOMA; META ANALYSIS; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SYSTEMATIC REVIEW; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84869487201     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0427     Document Type: Article

References (72)

1. World Health Organization. Skin Cancers -How Common Is Skin Cancer? Available at http://www.who.int/uv/faq/skincancer/en/index1.html, accessed August 10, 2011.
2. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
3. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009;9: 587-595.
4. Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-4745.
5. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
6. Korn EL, Liu PY, Lee SJ et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-534.
7. Howlader N, Noone AM, Krapcho M et al.; National Cancer Institute. SEER Cancer Statistics Review, 1975-2008. Available at http://seer.cancer.gov/csr/1975_2008, accessed August 8, 2011.
8. Sasse AD, Sasse EC, Clark LG et al. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007;(1): CD005413.
9. Eggermont AM, Robert C. New drugs in melanoma: It's a whole new world. Eur J Cancer 2011;47:2150-2157.
10. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: What have we learned in 30 years? Eur J Cancer 2004;40:1825-1836.
11. Petrella T, Quirt I, Verma S et al. Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Single-agent interleukin-2 in the treatment of metastatic melanoma: A systematic review. Cancer Treat Rev 2007;33:484-496.
12. Trinh VA. Current management of metastatic melanoma. Am J Health System Pharm 2008;65(suppl 9): S3-S8.
13. Coit DG, Andtbacka R, Bichakjian CK et al. NCCN Melanoma Panel. Melanoma. J Natl Compr Canc Netw 2009;7:250-275.
14. Dummer R, Hauschild A, Guggenheim M et al. ESMO Guidelines Working Group. Melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5):v194-v197.
15. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
16. U.S. Food and Drug Administration. FDA News Release: FDA Approves New Treatment for a Type of Late-Stage Skin Cancer. Available at http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm1193237.htm, accessed August 8, 2011.
17. European Medicines Agency. Yervoy (ipilimumab). Available at http://www.ema.europa.eu/ema/index.jsp?curl_pages/medicines/human/medicines/002213/human_med_001465.jsp&mid_WC0b01ac058001d124, accessed November 3, 2011.
18. Kotapati S, Dequen P, Ouwens M et al. Overall survival (OS) in the management of pretreated patients with unresectable stage III/IV melanoma: A systematic literature review and meta-analysis. J Clin Oncol 2011;29(15 suppl):8580.
19. Bucher HC, Guyatt GH, Griffith LE et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-691.
20. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002;21:2313-2324.
21. Salanti G, Higgins JP, Ades AE et al. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301.
22. Jansen JP, Fleurence R, Devine B et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health 2011;14: 417-428.
23. Hoaglin DC, Hawkins N, Jansen JP et al. Conducting indirect-treatment-comparisons and network-metaanalysis studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2. Value Health 2011;14:429-437.
24. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-3124.
25. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: Combining direct and indirect evidence. BMJ 2005;331:897-900.
26. Ades AE. A chain of evidence with mixed comparisons: Models for multi-parameter synthesis and consistency of evidence. Stat Med 2003;22:2995-3016.
27. Salanti G, Dias S, Welton NJ et al. Evaluating novel agent effects in multiple-treatments meta-regression. Stat Med 2010;29:2369-2383.
28. Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol 2011;11:61.
29. Ouwens M, Philips Z, Jansen JP. Network meta-analysis of parametric survival curves. Res Synth Methods 2010;1:258-271.
30. Dempster AP. The direct use of likelihood for significance testing. Stat Comput 1997;7:247-252.
31. Spiegelhalter DJ, Best NG, Carlin BP et al. Bayesian measures of model complexity and fit. J R Stat Soc Series B Stat Methodol 2002;64:583-639.
32. Lunn DJ, Thomas A, Best N et al. WinBUGS-a Bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput 2000;10:325-337.
33. Schwartzentruber DJ, Lawson DH, Richards JM et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364: 2119-2127.
34. Agarwala SS, Glaspy J, O'Day SJ et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002;20:125-133.
35. Agarwala SS, Ferri W, Gooding W et al. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 1999;85:1979-1984.
36. Ahmann DL, Hahn RG, Bisel HF. Clinical evaluation of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxam-ide (NSC-45388), melphalan (NSC-8806), and hydroxyurea (NSC-32065) in the treatment of disseminated malignant melanoma. Cancer Chemother Rep 1972;56:369-372.
37. Atkins MB, Hsu J, Lee S et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008;26:5748-5754.
38. Atzpodien J, Neuber K, Kamanabrou D et al. Combination chemotherapy with or without s.c. IL-2 and IFN-α: Results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002;86: 179-184.
39. Carter RD, Krementz ET, Hill GJ 2nd et al. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). Cancer Treat Rep 1976;60: 601-609.
40. Melanoma Study Group of the Mayo Clinic Cancer Center, Celis E. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: Evidence of systemic immune dysfunction. Cancer 2007;110:203-214.
41. Chiarion Sileni V, Nortilli R, Aversa SM et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 2001;11: 189-196.
42. Costanza ME, Nathanson L, Schoenfeld D et al. Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 1977;40:1010-1015.
43. Dorval T, Négrier S, Chevreau C et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-α-2a in patients with metastatic melanoma: A Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 1999;85:1060-1066.
44. Du Bois JS, Trehu EG, Mier JW et al. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 1997;15:1052-1062.
45. Eisen T, Trefzer U, Hamilton A et al. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer 2010;116:146-154.
46. Eton O, Legha SS, Bedikian AY et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 2002;20:2045-2052.
47. Glover D, Ibrahim J, Kirkwood J et al. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: An Eastern Cooperative Oncology Group study (E1686). Melanoma Res 2003; 13:619-626.
48. Hauschild A, Agarwala SS, Trefzer U et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27: 2823-2830.
49. Hersh EM, O'Day SJ, Powderly J et al. ePub 2010) A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Investig New Drugs 2011;29:489-498.
50. Hill GJ 2nd, Metter GE, Krementz ET et al. DTIC and combination therapy for melanoma. II. Escalating schedules of DTIC with BCNU, CCNU, and vincristine. Cancer Treat Rep 1979;63:1989-1992.
51. Johnston SR, Constenla DO, Moore J et al. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon α (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 1998; 77:1280-1286.
52. Keilholz U, Goey SH, Punt CJ et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997; 15:2579-2588.
53. Kirkwood JM, Lee S, Moschos SJ et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-α2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 2009;15:1443-1451.
54. Koretz MJ, Lawson DH, York RM et al. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer. Arch Surg 1991;126:898-903.
55. Luikart SD, Kennealey GT, Kirkwood JM. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 1984;2:164-168.
56. Maio M, Mackiewicz A, Testori A et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol 2010;28:1780-1787.
57. McDermott DF, Sosman JA, Gonzalez R et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 Study Group. J Clin Oncol 2008;26:2178-2185.
58. Mornex F, Thomas L, Mohr P et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003;13:97-103.
59. Nicholson S, Guile K, John J et al. A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/-low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma Res 2003;13:389-393.
60. O'Day S, Gonzalez R, Lawson D et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol 2009;27: 5452-5458.
61. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-975.
62. Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-632.
63. Rusthoven JJ, Quirt IC, Iscoe NA et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14:2083-2090.
64. Slingluff C, Lee SJ, Chianese-Bullock KA et al. First report of a randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells in patients with metastatic melanoma: An Eastern Cooperative Oncology Group Study (E1602). J Clin Oncol 2010;28(15 suppl):8508.
65. Slingluff CL Jr, Petroni GR, Yamshchikov G et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colonystimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-4026.
66. Sparano JA, Fisher RI, Sunderland M et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993;11:1969-1977.
67. Weber J, Thompson JA, Hamid O et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-5598.
68. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-164.
69. Zimpfer-Rechner C, Hofmann U, Figl R et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: A multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 2003;13:531-536.
70. Ribas A, Kim KB, Schuchter LM et al. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011;29:(15 suppl):8509.
71. Chapman PB, Hauschild A, Robert C et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
72. Clinicaltrials.gov. Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab. BMS Clinical Trials Disclosure. Available at http://clinicaltrials.gov/ct2/show/NCT01515189, accessed February 28, 2012.